Sistema de Salut de Catalunya
Institut Català de la Salut
[Vahdat LT] Weill Cornell Medicine, New York, NY, USA. [Schmid P] Center for Experimental Cancer Medicine, Barts Cancer Institute, London, UK. [Forero-Torres A] University of Alabama School of Medicine, Birmingham, AL, USA. [Blackwell K] Duke University Medical Center, Durham, NC, USA. [Telli ML] Stanford University School of Medicine, Stanford, CA, USA. [Melisko M] University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-02-22T11:26:34Z
2022-02-22T11:26:34Z
2021-05-20
Breast cancer; Cancer
Càncer de mama; Càncer
Cáncer de mama; Cáncer
The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m2 PO daily d1–14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.
Funding provided by Celldex Therapeutics, Inc.
Article
Published version
English
Mama - Càncer - Tractament; Metàstasi; Avaluació de resultats (Assistència sanitària); DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
Nature Research
NPJ Breast Cancer;7
https://doi.org/10.1038/s41523-021-00244-6
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
